Triglyceride concentration and ischemic heart disease: An eight-year follow-up in the Copenhagen Male Study

Circulation

Volumn 97, Issue 11, 1998, Pages 1029-1036

  Jeppesen, Jørgen ^a   Hein, Hans Ole ^b   Suadicani, Poul ^b   Gyntelberg, Finn ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b NONE

Author keywords

Coronary disease; Lipids; Lipoproteins; Risk factors

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032562257     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.11.1029     Document Type: Article

References (50)

1. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:2-14.
2. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. NIH Consenus Conference: Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. JAMA. 1993;269:505-510.
3. Garber AM, Avins AL. Triglyceride concentration and coronary heart disease [editorial; comment] [see comments]. BMJ 1994;309:2-3.
4. Schonfeld G. Inherited disorders of lipid transport Endocrinol Metab Clin North Am. 1990;19:229-257.
5. Hein HO, Sørensen H, Suadicani P, Gyntelberg F. Alcohol consumption, Lewis phenotypes, and risk of ischaemic heart disease. Lancet 1993;341: 392-396.
6. Hein HO, Suadicani P, Gyntelberg F. Alcohol consumption, seum low density lipoprotein cholesterol, and risk of ischaemic heart disease: six year follow up in the Copenhagen Male Study BMJ. 1996;312:736-741.
7. Siedel J, Klose S, Ziegenhorn J, Wahlefeld AW. Improved regent for the determination of serum cholesterol J Clin Chem Biochem 1981;19: 838-839.
8. Stahler F, Gruber W, Stinshoff K, Roshlau P. Eine praxis gerechte enzymatische Cholesterin-Bestimmung Med Lab. 1977;30:29-37.
9. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. Lipid Res. 1970;11:583-595.
10. Lopes-Virella MF. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem.1977;23:882-884.
11. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
12. Castelli WP, Epidemiology of triglycerides a view from Framingham. Am J Cardiol. 1992;70:3H-9H.
13. Rose GA, Holland WW, Crowley EA. A Sphygmomanomaeter for epidemiologists. Lancet. 1964;1:296-300.
14. Suadican P, Hein HO, Gyntelberg F. Serum validated tobacco use and social inequalines in risk of ischaemic heart disease. Int J Epidemiol. 1994; 23:293-300.
15. Svalastoga K. Prestige, Calss, and Motility. Copenhagen. Denmark: Munksgaard: 1959.
16. Mabeck CE, Wichmann B. Case of death and death certificates: assessment of the diagnoses in 373 death certificates (in Danish) Ugeskr Lager. 1980; 142:257-261.
17. Asnæs S, Østergaard K. Reliability of death cdritficates: an autopsy investigation (in Danish). Ugeskr Læger 1980;142:265-266.
18. Asnæs S, Mabeck CE, Wichmann B. The significance of autopsies for statistics concerining causes of death: an investigation of death certificates (in Danish). Ugeskr Lager 1980;142:261-264.
19. Madsen M, Balling H, Eriksen LS. The validity of the diagnosis of acute myocardial infaraction in two Danish registers: the Heart Register compared with the National Patient Register (in Danish). Ugeskar Læger 1990;152: 308-314.
20. Mosbech J, Jørgensen J, Madesen M, Rostgaard K. Thornberg K, Poulsen TD. The Danish National patient Register evaluation of data quality (in Danish). Ugeskar Læger. 1995;157:3741-3745.
21. Norusis M. SPSS/PC+ Base Manual. Chicago. Ill SSPC Inc USA: 1988.
22. Norusis M. SPSS/PC+ Advanced Statistics. Chicago. Ill: SSPS Inc USA: 1988.
23. Kannel WB, Wilson PWF. Efficacy of lipid profiles in predication of coronary disease. Am Heart J. 1992;124:768-774.
24. Litell HO, Pollare T, Berne C, Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters J Cardiovasc Pharmacol. 1990;15(suppl 5):S46-S52.
25. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR, O'Grady KH, Davis CE. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993;328: 1220-1225.
26. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factor for major coronary events in middle-aged men. Am J Cardiol. 1996;77:1179-1184.
27. Bainton D, Miller NE , Bolton CH, Yarnell JWG, Sweetnam PM, Baker IA, Lewis B, Elwood PC. Plasma triglyceride and high density lipoprotein cholesterol as predicators of ischaemic heart disease in British men: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J 1992;68:60-66.
28. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for level: a meta-analysis fo population of high-density lipoprotein cholestersol : A meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
29. Barter PJ, Rye K-A. High density lipoproteins and coronary heart disease Atherosclerosis. 1996;121:1-12.
30. Pyörälä K, Laakso Markku. Uusitupa M. Diabetes and atherosclerosis an epidemiologic view. Diabetes Metab Rev. 1987;3:463-524.
31. Assman G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992;70:733-737.
32. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH. Joint effectsm of serum triglycerdie and LDL cholesterl and HDL cholestrol concertrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:37-45.
33. Steinberg D, Witztum JL. Lipoproteins and athetrogenesis: current concepts. JAMA. 1990; 264:3047-3052.
34. Mack WJ, Krauss RM, Hodis HN, Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS): treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol. 1996;16:697-704.
35. Nordestgaard BG, Tybjaerg-Hansen A. IDL, VLDL. Chylormicrons and atherosckerosis. Eur J Epidemiol. 1992;8:92-98.
36. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WS, Krauss RM. Low-density lipoprotein subclass pattens and risk of myocardial infaction. JAMA. 1988;260:1917-1922.
37. Lahdenpera S, Tilly-Kiesi M, Vuorinen-Markkola H, Kuusi T, Taskinen MR. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care. 1993;16:584-592.
38. Hamsten A, Wiman B, Defaire U, Blomback M. Incresed Plasma level of a rapid inhibitor of tissue plasminogen activator in young surviours of myocardial infriaction. N Engl J Med. 1985;313:1557-1563.
39. Metha J, Mehra P, Lawason D, Saldeen T. Plasma tissue plasminogen activator inhiobitor of tissue Plasminogen activator in young surviuors of serum triglyceride concentratins J Am Coll Cardiol 1987;9:263-268.
40. Reaven GM, Role of insulin resistance in human diseses Diabetes. 1988; 37;1595-1607.
41. Wingard DL, Barrett-Connor EL, Ferrara A. Is insulin really a heart disease risk faactor: Diabetes Care 1995;18:1299-1304.
42. Depries JP, Lamache B, Mauriege P, Cantin B, Dagensais GR, Moorjam S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease N Engl J Med 1996;334:952-957.
43. Hagerup L, Eriksen M, Schroll M, Hollnagel H, Agner E, Larsen S. The Glostrup Population Studies collection of epidemiologic tables. Scand J Soc Med. 1931;20(suppl): 1-112.
44. fontbonne A, Eschwège E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warned JM, Claude JR, Rosselin GE. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia. 1981;32:300-304.
45. Laakso M, Lehto S, Penttilä I, Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 1993;88:1421-1430.
46. Blankenhorn DH, Azen SP, Kramisch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, Denoer LWV, Mahrer PR, Masteller MJ,Vailas LI, Alaupovic P, Hirsch LJ, and the MARS Research Group. Coronary angiographic changes with lovastain therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
47. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Elankenborn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-49.
48. Anger E. Some cardiovascular risk markers are also important in old age. Acta Med Scand Suppl. 1985;696:3-50.
49. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlance PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1310-1317.
50. Pyörää K, De Backer G, Graham I, Poole-Wilson P, Wood D, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardilogy, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300-1331.